Xortx therapeutics announces publication of mt. sinai study of hospitalized covid-19 patients

Calgary, alberta, dec. 10, 2021 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anu), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to highlight and announce the online publication of the peer reviewed paper entitled “prevalence and outcomes associated with hyperuricemia in hospitalized patients with covid-19” in the american journal of nephrology and available at the link below.
XRTX Ratings Summary
XRTX Quant Ranking